Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 7;12:877635. doi: 10.3389/fonc.2022.877635

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Lang, Leal, Marín-Jiménez, Hartman, Shulman, Navarro, Lewis, Capasso, Bagby, Yacob, MacBeth, Freed, Eckhardt, Jordan, Blatchford, Pelanda, Lieu, Messersmith and Pitts

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Reduced tumor growth in CRC MSS PDXs in HIS-BRGS mice treated with nivolumab, cabozantinib and their combination. (A) Experimental timeline for HIS-BRGS studies testing TKI/ICB treatments in five distinct CRC MSS PDX studies. Each PDX was tested in HIS-BRGS mice generated from a unique CB. (B) The distribution of number of tumors with specific growing rates (SGR) among all CRC PDX tumors in the HIS-BRGS studies (left panel); the normalized SGR among tumors in the nivolumab (N), cabozantinib (Ca) and their combination (Ca/N) treatment groups compared to untreated (V=vehicle) mice (middle panel); and CRC tumor weights at harvest in same treatment groups (right panel). P-values indicate ANOVA multiple comparisons with Welch’s correction: *p < 0.05, ***p < 0.001, ****p < 0.0001 or as indicated by number.